rawfin.tv
BMS, Ono Sue Amgen Over Opdivo Biosimilar Ahead of FDA Decision
RegulationstocksAI Generated

BMS, Ono Sue Amgen Over Opdivo Biosimilar Ahead of FDA Decision

By rawfin.tv Markets Desk||1 min read|AI-assisted · Methodology

Bristol Myers Squibb and Ono Pharmaceutical are challenging Amgen's proposed Opdivo biosimilar through a lawsuit, alleging patent infringement. The legal action comes as the FDA's decision on the biosimilar's approval approaches, creating uncertainty in the oncology market.

BMYAMGNPharmaceuticalsPatent DisputeFDA Regulation

Related Articles

Adidas Surges 37% to Record Q3 Profit, Lifts Full-Year Targets

Adidas Surges 37% to Record Q3 Profit, Lifts Full-Year Targets

stocks
EQT to Acquire Cleanaway Waste for $6.5 Billion

EQT to Acquire Cleanaway Waste for $6.5 Billion

stocks
S&P 500 Breaches Key Support as AI Sell-Off Pressures Tech Sector

S&P 500 Breaches Key Support as AI Sell-Off Pressures Tech Sector

stocks
US Chip Stocks Plunge 16% in Longest Losing Streak Since 2008

US Chip Stocks Plunge 16% in Longest Losing Streak Since 2008

stocks